Histopathological Changes In Corneas Of Patients With Mucopolysaccharidosis Type Vi That Underwent Penetrating Keratoplasty
Published 2022 - 40th Congress of the ESCRS
Reference: PP02.02 | Type: ESCRS 2022 - Posters | DOI: 10.82333/d88r-7s97
Authors: Ana Faria Pereira* 1 , Sofia Pedrosa 2 , Augusto Magalhães 1 , Raul Moreira 1 , João Costa 1 , Elisa Leão-Teles 3 , Fernando Falcão-Reis 1
1Department of Ophthalmology,Centro Hospitalar e Universitário de São João,Porto,Portugal, 2Department of Pathology,Centro Hospitalar e Universitário de São João,Porto,Portugal, 3Department of Pediatrics, Reference Centre of Inherited Metabolic Diseases,Centro Hospitalar e Universitário de São João,Porto,Portugal
Purpose
Mucopolysaccharidosis (MPS) are a group of diseases caused by accumulation of undegraded glycosaminoglycans (GAGs). MPS VI is a rare autosomal recessive disease caused by deficiency in N-acetylgalactosamine-4-sulfatase. Ocular manifestations are frequent and include corneal opacity, caused by accumulation of GAGs in corneal layers, inducing light scattering. In these cases, the only current treatment is corneal transplantation, usually penetrating keratoplasty (PK) or deep anterior lamellar keratoplasty (DALK).The main purpose of this study is to identify the histopathological characteristics of corneas of patients with MPSVI and based on these characteristics, determine the most suitable surgical approach in corneal surgery in these cases.
Setting
Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Methods
This study includes the corneas of four MPS VI patients which have been submitted to PK for corneal clouding. Specimens of primitive corneas were examined using hematoxylin/eosin, special trichrome, colloidal iron and periodic acid-Schiff stains.
Results
Conclusions
Descemet membrane and endothelium can remain unaffected until later stages of disease progression. In such cases the surgical treatment should consist of DALK. However our study revealed the presence of deposits in all corneal layers in most cases suggesting that older patients with more severe forms of disease must be treated with PK. MPSVI is a disabling disease in which historically palliative care was the only option. Fortunately, the current therapeutic modalities, including hematopoietic stem cell transplantation and enzyme replacement therapy have increased life span and life quality in affected patients. Currently, these patients require differentiated multidisciplinary care, which includes ophthalmic surgery in specialized centers.